Based on the key measurements obtained from MediciNova's financial statements, MediciNova is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, MediciNova's Total Current Liabilities is fairly stable compared to the past year. Property Plant And Equipment Net is likely to climb to about 652.3 K in 2024, whereas Total Stockholder Equity is likely to drop slightly above 50.9 M in 2024. Key indicators impacting MediciNova's financial strength include:
The financial analysis of MediciNova is a critical element in measuring its lifeblood. Investors should not minimize MediciNova's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(9 Million)
MediciNova
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Sales General And Administrative To Revenue
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Other Non Cash Items
Sale Purchase Of Stock
Total Cashflows From Investing Activities
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Account Receivables
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Exchange Rate Changes
Change To Operating Activities
Issuance Of Capital Stock
Total Assets
Total Stockholder Equity
Retained Earnings
Other Assets
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Stockholder Equity
Total Liab
Other Current Liab
Total Current Liabilities
Property Plant And Equipment Net
Net Debt
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Non Current Liabilities Total
Other Current Assets
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Other Liab
Non Currrent Assets Other
Accumulated Other Comprehensive Income
Property Plant Equipment
Treasury Stock
Short Long Term Debt Total
Current Deferred Revenue
Good Will
Short Term Debt
Intangible Assets
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Deferred Long Term Liab
Long Term Investments
Net Invested Capital
Net Working Capital
Capital Stock
Non Current Liabilities Other
Capital Lease Obligations
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Tax Expense
Depreciation And Amortization
Income Before Tax
Total Other Income Expense Net
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Cost Of Revenue
Net Income From Continuing Ops
Non Operating Income Net Other
Net Income Applicable To Common Shares
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past MediciNova Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of MediciNova's financial statements are interrelated, with each one affecting the others. For example, an increase in MediciNova's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in MediciNova's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MediciNova. Check MediciNova's Beneish M Score to see the likelihood of MediciNova's management manipulating its earnings.
MediciNova Stock Summary
MediciNova competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California. Medicinova operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what MediciNova's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining MediciNova's current stock value. Our valuation model uses many indicators to compare MediciNova value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across MediciNova competition to find correlations between indicators driving MediciNova's intrinsic value. More Info.
MediciNova is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, MediciNova's Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value MediciNova by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
MediciNova Systematic Risk
MediciNova's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. MediciNova volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on MediciNova correlated with the market. If Beta is less than 0 MediciNova generally moves in the opposite direction as compared to the market. If MediciNova Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one MediciNova is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of MediciNova is generally in the same direction as the market. If Beta > 1 MediciNova moves generally in the same direction as, but more than the movement of the benchmark.
MediciNova Thematic Clasifications
MediciNova is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in MediciNova Stock are looking for potential investment opportunities by analyzing not only static indicators but also various MediciNova's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of MediciNova growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of MediciNova help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of MediciNova. We use our internally-developed statistical techniques to arrive at the intrinsic value of MediciNova based on widely used predictive technical indicators. In general, we focus on analyzing MediciNova Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build MediciNova's daily price indicators and compare them against related drivers.
When running MediciNova's price analysis, check to measure MediciNova's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MediciNova is operating at the current time. Most of MediciNova's value examination focuses on studying past and present price action to predict the probability of MediciNova's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MediciNova's price. Additionally, you may evaluate how the addition of MediciNova to your portfolios can decrease your overall portfolio volatility.